This patent teaches the in vivo use of dithiocarbamate for hematopoietic reconstitution after bone marrow transplantation or myelosuppression.
The dithiocarbamate or its analogs that are mentioned in the patent may be administered systemically without adverse effects.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.